LIMS1 risk genotype and T cell-mediated rejection in kidney transplant recipients.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
09 11 2021
Historique:
received: 23 01 2021
pubmed: 29 4 2021
medline: 20 1 2022
entrez: 28 4 2021
Statut: ppublish

Résumé

This study aims to examine the association of LIM zinc finger domain containing 1 (LIMS1) genotype with allograft rejection in an independent kidney transplant cohort. We genotyped 841 kidney transplant recipients for the LIMS1 rs893403 variant by Sanger sequencing followed by polymerase chain reaction confirmation of the deletion. Recipients who were homozygous for the LIMS1 rs893403 genotype GG were compared with the AA/AG genotypes. The primary outcome was T cell-mediated or antibody-mediated rejection (TCMR or ABMR, respectively) and secondary outcome was allograft loss. After a median follow-up of 11.4 years, the rate of TCMR was higher in recipients with the GG genotype (n = 200) compared with the AA/AG genotypes (n = 641) [25 (12.5%) versus 35 (5.5%); P = 0.001] while ABMR did not differ by genotype [18 (9.0%) versus 62 (9.7%)]. Recipients with the GG genotype had 2.4 times higher risk of TCMR than those who did not have this genotype [adjusted hazard ratio2.43 (95% confidence interval 1.44-4.12); P = 0.001]. A total of 189 (22.5%) recipients lost their allografts during follow-up. Kaplan-Meier estimates of 5-year (94.3% versus 94.4%; P = 0.99) and 10-year graft survival rates (86.9% versus 83.4%; P = 0.31) did not differ significantly in the GG versus AA/AG groups. Our study demonstrates that recipient LIMS1 risk genotype is associated with an increased risk of TCMR after kidney transplantation, confirming the role of the LIMS1 locus in allograft rejection. These findings may have clinical implications for the prediction and clinical management of kidney transplant rejection by pretransplant genetic testing of recipients and donors for LIMS1 risk genotype.

Sections du résumé

BACKGROUND
This study aims to examine the association of LIM zinc finger domain containing 1 (LIMS1) genotype with allograft rejection in an independent kidney transplant cohort.
METHODS
We genotyped 841 kidney transplant recipients for the LIMS1 rs893403 variant by Sanger sequencing followed by polymerase chain reaction confirmation of the deletion. Recipients who were homozygous for the LIMS1 rs893403 genotype GG were compared with the AA/AG genotypes. The primary outcome was T cell-mediated or antibody-mediated rejection (TCMR or ABMR, respectively) and secondary outcome was allograft loss.
RESULTS
After a median follow-up of 11.4 years, the rate of TCMR was higher in recipients with the GG genotype (n = 200) compared with the AA/AG genotypes (n = 641) [25 (12.5%) versus 35 (5.5%); P = 0.001] while ABMR did not differ by genotype [18 (9.0%) versus 62 (9.7%)]. Recipients with the GG genotype had 2.4 times higher risk of TCMR than those who did not have this genotype [adjusted hazard ratio2.43 (95% confidence interval 1.44-4.12); P = 0.001]. A total of 189 (22.5%) recipients lost their allografts during follow-up. Kaplan-Meier estimates of 5-year (94.3% versus 94.4%; P = 0.99) and 10-year graft survival rates (86.9% versus 83.4%; P = 0.31) did not differ significantly in the GG versus AA/AG groups.
CONCLUSIONS
Our study demonstrates that recipient LIMS1 risk genotype is associated with an increased risk of TCMR after kidney transplantation, confirming the role of the LIMS1 locus in allograft rejection. These findings may have clinical implications for the prediction and clinical management of kidney transplant rejection by pretransplant genetic testing of recipients and donors for LIMS1 risk genotype.

Identifiants

pubmed: 33909908
pii: 6257443
doi: 10.1093/ndt/gfab168
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
LIM Domain Proteins 0
LIMS1 protein, human 0
Membrane Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2120-2129

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Auteurs

Yasar Caliskan (Y)

Division of Nephrology, Saint Louis University, St. Louis, MO, USA.
Division of Nephrology, Istanbul University School of Medicine, Istanbul, Turkey.

Gonca Karahan (G)

Department of Medical Biology, Istanbul University School of Medicine, Istanbul, Turkey.
Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Sebahat Usta Akgul (SU)

Department of Medical Biology, Istanbul University School of Medicine, Istanbul, Turkey.

Safak Mirioglu (S)

Division of Nephrology, Istanbul University School of Medicine, Istanbul, Turkey.

Yasemin Ozluk (Y)

Department of Pathology, Istanbul University School of Medicine, Istanbul, Turkey.

Halil Yazici (H)

Division of Nephrology, Istanbul University School of Medicine, Istanbul, Turkey.

Erol Demir (E)

Division of Nephrology, Istanbul University School of Medicine, Istanbul, Turkey.

Ahmet B Dirim (AB)

Division of Nephrology, Istanbul University School of Medicine, Istanbul, Turkey.

Aydin Turkmen (A)

Division of Nephrology, Istanbul University School of Medicine, Istanbul, Turkey.

John Edwards (J)

Division of Nephrology, Saint Louis University, St. Louis, MO, USA.

Fatma Oguz Savran (FO)

Department of Medical Biology, Istanbul University School of Medicine, Istanbul, Turkey.

Mehmet S Sever (MS)

Division of Nephrology, Istanbul University School of Medicine, Istanbul, Turkey.

Krzysztof Kiryluk (K)

Division of Nephrology, Columbia University Medical Center, New York City, NY, USA.

Ali Gharavi (A)

Division of Nephrology, Columbia University Medical Center, New York City, NY, USA.

Krista L Lentine (KL)

Division of Nephrology, Saint Louis University, St. Louis, MO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH